A Phase 2 Trial of Everolimus and Pasireotide Long Acting Release in Patients with Metastatic Uveal Melanoma

OBJECTIVES: Test the hypothesis that inhibiting mammalian target of rapamycin (mTOR) and Insulin Growth Factor-1 Receptor would be efficacious in metastatic uveal melanoma. METHODS: Phase 2 trial of everolimus 10mg daily plus pasireotide long-acting release 60mg every 28 days enrolling patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Melanoma Res
Main Authors: Shoushtari, Alexander N., Ong, Leonard T., Schoder, Heiko, Singh-Kandah, Shahnaz, Abbate, Kelly, Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd, Chapman, Paul B., Panageas, Katherine S., Schwartz, Gary K., Carvajal, Richard D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553199/
https://ncbi.nlm.nih.gov/pubmed/26795274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000234
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados